Loading patent…
AssigneesH. Lee Moffitt Cancer Center and Research Institute, Inc., Board of Regents, The University of Texas System
InventorsAmod A Sarnaik, Jeffrey S. Weber, Shari Pilon-Thomas, Laszlo G. Radvanyi, Jessica Ann Chacon, James J. Mule, MacLean S. Hall
Estimating the term…
Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.
A method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT), comprising culturing tumor fragments from the subject in a culture medium comprising IL-2 and a 4 IBB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity.
Dependencies are inferred from the claim text.